EMA issued a concept paper in late February revising its immunogenicity assessment guideline. The aim of the revision is to clarify how immunogenicity data is presented, to introduce a risk-based approach, and to determine the appropriate studies needed for different products. [For a discussion of the quality/immunogenicity relationship, see IPQ January 9, 2014.]
[/membership][membership level=”0,4″][The content continues for paid members only.]
Login or Subscribe [/membership][membership level=”1,5,6,7,8,9,10,11,12″][membership]
